Companies
Vertex Pharmaceuticals
S&P 500Health Care· USA

VRTX

Status-Quo-Player

Vertex Pharmaceuticals

$440.05

+0.86%

Open $434.17·Prev $436.29

as of 13 Apr

STATUS-QUO-PLAYER

Power Core

Power Core in one sentence: Vertex's moat is the compounding molecular complexity of the CFTR protein itself, which has defeated every external challenger's drug design efforts for over a decade, transforming a patent-protected franchise into a biology-protected monopoly.

Published1 Apr 2026
UniverseS&P 500
SectorHealth Care

Direction of Movement

Upward, Compounding Through Franchise Depth and Pipeline Breadth

ROC 200

-2.7%

This page is for informational purposes only and does not constitute investment advice. L17X Research is an independent research service.
VRTX — Vertex Pharmaceuticals — Power Mapping Analysis — L17X — L17X